BIBW2992 is a highly potent, irreversible dual EGFR/HER2 tyrosine kinase inhibitor potentially efficacious in the treatment of cancers dependent on EGFR/HER2 signaling. Genetic alterations in the kinase domain of the epidermal growth factor receptor (EGFR) in non-small cell lung cancer (NSCLC) patients are associated with sensitivity to treatment with small molecule tyrosine kinase inhibitors. Although first-generation reversible, ATP-competitive inhibitors showed encouraging clinical responses in lung adenocarcinoma tumors harboring such EGFR mutations, almost all patients developed resistance to these inhibitors over time. Such resistance to first-generation EGFR inhibitors was frequently linked to an acquired T790M point mutation in the kinase domain of EGFR, or upregulation of signaling pathways downstream of HER3. Overcoming these mechanisms of resistance, as well as primary resistance to reversible EGFR inhibitors driven by a subset of EGFR mutations, will be necessary for development of an effective targeted therapy regimen. BIBW2992, an anilino-quinazoline is designed to irreversibly bind EGFR and HER2, potently suppresses the kinase activity of wild-type and activated EGFR and HER2 mutants, including erlotinib-resistant isoforms. Consistent with this activity, BIBW2992 suppresses transformation in isogenic cell-based assays, inhibits survival of cancer cell lines and induces tumor regression in xenograft and transgenic lung cancer models, with superior activity over erlotinib. These findings encourage further testing of BIBW2992 in lung cancer patients harboring EGFR or HER2 oncogene. In particular, NSCLC patients with tumors that harbor either primary (exon 20 insertion) or acquired (T790M) erlotinib resistance mutations might be ideal candidates for BIBW2992 treatment. On the other hand, NSCLC patients with primary resistance to first-generation EGFR inhibitors due to the previously mentioned KRAS mutations, or acquired resistance due to amplification of the MET protooncogene, would not be expected to respond to treatment with BIBW2992 alone. FGFR can stimulate proliferation and take part in regulating the transform of cells in pathological process. There are many paralleled ways to achieve the signal transmission of FGFR- mediated cell division. Many reports have confirmed FGFR1 produces a strong signal transmission because of many key residues of amino acid. It’s confirmed that FGFR-1 is very important for the cell migration in vivo. The method of genetics has confirmed similar things of FGFR exist in Drosophila melanogaster, they are important for the migration of cells and the formation of tubular branch in the developing progress. 3.skeletal disorde The growth and differentiation of skeleton is also regulated by FGFR, the mutation of FGFR will cause skeletaldeformity. For example, cartilage dysplasia and midgetism are related to the mutation of FGFR3. Dosage and usage: the recommended daily dosage of TARCEVA is 150mg,which is taken one hour befor meal or two hours after meal.Do not stop taking the drug until the disease develops or unacceptable side effect occurs. Two other clinical trials TALENTn=1172and TRIBUTE (n = 1059) come to a conclusion: there is no clinical benefit to combine TARCEVA with chemotherapy regimens containing cisplatin(Carboplatin+ Taxol) in the treatment of locally advanced or metastasizing NSCLC patients.So these combinational regimens are not recommended. IRESSA may be replaced by TARCEVA to be a third-line drug in the treatment of NSCLC. Untoward effect: the most common untoward effects on patients who receive a treatment of TARCEVA are rash, diarrhea, anorexia and fatigue. Ffter a period of time about 8â€12 months, the cancer cells become resistant to the treatment of Erlotinib. Tt is due to a second mutation of EGFR called Posts related: Afatinib (BIBW 2992) triples progression free survival in phase III study in lung cancer patients Afatinib (BIBW-2992, Tomtovok) wins a battle (PFS) but loses the war (OS) for EGFR TKI-sensitive patients
Please Rate this Article 5 out of 54 out of 53 out of 52 out of 51 out of 5
Not yet Rated
